Theseus Pharmaceuticals Inc (THRX) Annual Income Statement

Annual · GAAP · USD millions
Access THRX quarterly income statements →
The data below summarizes Theseus Pharmaceuticals Inc's income statement results from to Dec 31 2022, enabling period-by-period comparison of operating performance.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2022)
2022
(Dec 31 2021)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing18.39
Research and Development Expense35.70
Total operating costs including COS54.09
Operating income / -loss-54.09
Net Interest (-)Expense / Income0.00
Other loss / -income-3.48
Total costs & expenses50.61
Income & Taxes
Income / -loss before income taxes-50.61
Income after income taxes-50.61
Income / -loss from continuing operations-50.61
Net income / -loss-50.61
Income / -loss to shareholder-50.61
EBIT-50.61
EBITD-50.56
EBITDA-50.56
Earnings Per Share
Basic EPS (excl. extra items)-1.31
Basic Net EPS-1.31
Basic shares outstanding (Mill. of Units)38.49
Diluted Net EPS-1.31
Diluted average shares (Mill. of Units)38.49
4 historic quarters locked

Sign in to unlock the full Theseus Pharmaceuticals Inc income statement history.

About THRX Annual Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-K filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-K filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.